162 related articles for article (PubMed ID: 32475213)
1. The use of the win odds in the design of non-inferiority clinical trials.
Peng L
J Biopharm Stat; 2020 Sep; 30(5):941-946. PubMed ID: 32475213
[TBL] [Abstract][Full Text] [Related]
2. A generalized analytic solution to the win ratio to analyze a composite endpoint considering the clinical importance order among components.
Dong G; Li D; Ballerstedt S; Vandemeulebroecke M
Pharm Stat; 2016 Sep; 15(5):430-7. PubMed ID: 27485522
[TBL] [Abstract][Full Text] [Related]
3. Win Statistics in Observational Cancer Research: Integrating Clinical and Quality-of-Life Outcomes.
Chiaruttini MV; Lorenzoni G; Spolverato G; Gregori D
J Clin Med; 2024 May; 13(11):. PubMed ID: 38892983
[No Abstract] [Full Text] [Related]
4. The stratified win ratio.
Dong G; Qiu J; Wang D; Vandemeulebroecke M
J Biopharm Stat; 2018; 28(4):778-796. PubMed ID: 29172988
[TBL] [Abstract][Full Text] [Related]
5. The win odds: statistical inference and regression.
Song J; Verbeeck J; Huang B; Hoaglin DC; Gamalo-Siebers M; Seifu Y; Wang D; Cooner F; Dong G
J Biopharm Stat; 2023 Mar; 33(2):140-150. PubMed ID: 35946932
[TBL] [Abstract][Full Text] [Related]
6. Weighted win loss approach for analyzing prioritized outcomes.
Luo X; Qiu J; Bai S; Tian H
Stat Med; 2017 Jul; 36(15):2452-2465. PubMed ID: 28343373
[TBL] [Abstract][Full Text] [Related]
7. On recurrent-event win ratio.
Mao L; Kim K; Li Y
Stat Methods Med Res; 2022 Jun; 31(6):1120-1134. PubMed ID: 35345957
[TBL] [Abstract][Full Text] [Related]
8. A win ratio approach to comparing continuous non-normal outcomes in clinical trials.
Wang D; Pocock S
Pharm Stat; 2016 May; 15(3):238-45. PubMed ID: 26970432
[TBL] [Abstract][Full Text] [Related]
9. Adjusting win statistics for dependent censoring.
Dong G; Huang B; Wang D; Verbeeck J; Wang J; Hoaglin DC
Pharm Stat; 2021 May; 20(3):440-450. PubMed ID: 33247544
[TBL] [Abstract][Full Text] [Related]
10. Generalized pairwise comparison methods to analyze (non)prioritized composite endpoints.
Verbeeck J; Spitzer E; de Vries T; van Es GA; Anderson WN; Van Mieghem NM; Leon MB; Molenberghs G; Tijssen J
Stat Med; 2019 Dec; 38(30):5641-5656. PubMed ID: 31659790
[TBL] [Abstract][Full Text] [Related]
11. Graphing the Win Ratio and its components over time.
Finkelstein DM; Schoenfeld DA
Stat Med; 2019 Jan; 38(1):53-61. PubMed ID: 30206956
[TBL] [Abstract][Full Text] [Related]
12. Large sample inference for a win ratio analysis of a composite outcome based on prioritized components.
Bebu I; Lachin JM
Biostatistics; 2016 Jan; 17(1):178-87. PubMed ID: 26353896
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of inferential methods for the net benefit and win ratio statistics.
Verbeeck J; Ozenne B; Anderson WN
J Biopharm Stat; 2020 Sep; 30(5):765-782. PubMed ID: 32097079
[TBL] [Abstract][Full Text] [Related]
14. The stratified win statistics (win ratio, win odds, and net benefit).
Dong G; Hoaglin DC; Huang B; Cui Y; Wang D; Cheng Y; Gamalo-Siebers M
Pharm Stat; 2023; 22(4):748-756. PubMed ID: 36808217
[TBL] [Abstract][Full Text] [Related]
15. Robust statistical inference for matched win statistics.
Matsouaka RA
Stat Methods Med Res; 2022 Aug; 31(8):1423-1438. PubMed ID: 35578578
[TBL] [Abstract][Full Text] [Related]
16. Risk difference, relative risk, and odds ratio for non-inferiority clinical trials with risk rate endpoint.
Ni S; Yu Q; Zhong Z; Yang M; Zhao Y; Wu J; Bai J; Yu H
J Biopharm Stat; 2023 Jan; 33(1):15-30. PubMed ID: 35791856
[TBL] [Abstract][Full Text] [Related]
17. An alternative approach to confidence interval estimation for the win ratio statistic.
Luo X; Tian H; Mohanty S; Tsai WY
Biometrics; 2015 Mar; 71(1):139-145. PubMed ID: 25156540
[TBL] [Abstract][Full Text] [Related]
18. Handling an uncertain control group event risk in non-inferiority trials: non-inferiority frontiers and the power-stabilising transformation.
Quartagno M; Walker AS; Babiker AG; Turner RM; Parmar MKB; Copas A; White IR
Trials; 2020 Feb; 21(1):145. PubMed ID: 32029000
[TBL] [Abstract][Full Text] [Related]
19. The win ratio: Impact of censoring and follow-up time and use with nonproportional hazards.
Dong G; Huang B; Chang YW; Seifu Y; Song J; Hoaglin DC
Pharm Stat; 2020 May; 19(3):168-177. PubMed ID: 31671481
[TBL] [Abstract][Full Text] [Related]
20. Fallacies of Using the Win Ratio in Cardiovascular Trials: Challenges and Solutions.
Ajufo E; Nayak A; Mehra MR
JACC Basic Transl Sci; 2023 Jun; 8(6):720-727. PubMed ID: 37426527
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]